



PRESS RELEASE

03 April 2024 15:00:00 CEST

AcouSort restructures its North American sales operation

AcouSort and the Company's Sales Director North America, Kelley Intehar, have mutually agreed to terminate their collaboration. The reason for the termination is that the North American sales have not developed in line with the Company's ambitions. The ongoing sales activities and continued business development in North America will temporarily be handled by AcouSort in Lund. The Company's long-term objective to establish profitable growth in North America remains unchanged.

"I want to thank Kelley Intehar for her contributions to AcouSort and wish her all the best in her future endeavors. Despite the disappointing sales development, Kelley has added important insights to our understanding of the North American market," says CEO Torsten Freltoft.

FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com

ABOUT ACOUSORT

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Carnegie Investment Bank AB (publ).